SCHEMBL29212344

SCHEMBL29212344

C#CCNc1ccc(S(C)(=O)=O)c2ccn(S(=O)(=O)c3ccccc3)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 19/20 0.40
▸ DRD3 P35462 5/20 0.37
▸ DRD2 P14416 4/20 0.37
▸ HTR1A P08908 3/20 0.37
▸ HTR1D P28221 2/20 0.37
▸ HTR1B P28222 2/20 0.37
▸ HTR1F P30939 2/20 0.37
▸ HTR7 P34969 2/20 0.37
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29212454 0.81 HTR6 (0.48) HTR6MEN1ALDH1A1LMNAHPGD
SCHEMBL25032365 0.77 HTR6 (0.44) HTR6DRD3DRD2HTR1AHTR1D
SCHEMBL30184592 0.77 HTR6 (0.44) HTR6DRD3DRD2HTR1AHTR1D
SCHEMBL31270507 0.76 HTR6 (0.39) HTR6MEN1KMT2AHDAC3HDAC4
SCHEMBL25032374 0.76 HTR6 (0.39) HTR6MEN1KMT2AHDAC3HDAC4
SCHEMBL29212284 0.72 HTR6 (0.41) HTR6DRD2HTR1AMEN1ALDH1A1
SCHEMBL31270117 0.72 HTR6 (0.35) HTR6DRD3DRD2HTR1AHTR1D
SCHEMBL29212327 0.70 HTR6 (0.43) HTR6DRD3HTR1AHTR1DHTR1B
SCHEMBL29212375 0.67 HTR6 (0.44) HTR6DRD3DRD2HTR1AHTR1D
SCHEMBL29212439 0.66 CA12 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119968361-A Compounds targeting p 53Y 220 mutants 北京加科思新药研发有限公司 2025-05-09 — — CN disclosed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
EP-4384510-A1 COMPOUNDS TARGETING MUTANT OF P53 Jacobio Pharmaceuticals Co., Ltd. (CN) 2024-06-19 — — EP disclosed
CN-117813295-A Compounds targeting p53 mutants 北京加科思新药研发有限公司 2024-04-02 — — CN disclosed
WO-2024041503-A1 COMPOUNDS TARGETING Y220C MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-02-29 — — WO disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 HTR6 3835/4885DRD3 4851/4885DRD2 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback